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ABSTRAK ABSTRACT
Tujuan: mengeksplorasi hubungan antara nefrostomi perkutan
dan kelangsungan hidup pasien kanker serviks stadium lanjut
disertai dengan gangguan ginjal.
Bahan dan Metode: Kohort retrospektif, dengan 70 sampel yang
diambil dengan consecutive sampling. Populasi adalah semua
penderita kanker serviks stadium lanjut dengan gangguan fungsi
ginjal (IIIB, IVA, IVB, rekurent) yang dirawat di RSUPNCM
sejak 1 Januari 1998. Besar sampel masing-masing 19 orang
untuk kelompok nefrostomi perkutan dan konservatif. Kesintasan
diukur dari data rekam medis penderita kanker serviks stadium
lanjut dengan gangguan fungsi ginjal yang dirawat di RSUPNCM
sejak 1 Januari 1998 sampai 31 Desember 2003. Nefrostomi
perkutan diukur dari data rekam medis penderita kanker serviks
stadium lanjut dengan gangguan fungsi ginjal yang dirawat di
RSUPNCM sejak 1 Januari 1998 sampai 31 Desember 2003.
Hasil: Median kesintasan dari  44 responden yang menjalani
nefrostomi perkutan adalah 203 hari dengan probabilitas
kesintasan pada bulan ke-6 sebesar 56,9% dan pada bulan ke-12
sebesar 31,1%. Median kesintasan dari 26 responden yang tidak
menjalani nefrostomi perkutan adalah 75 hari dengan peluang
kesintasan pada bulan ke-6 sebesar 26,6% dan pada bulan ke 12
sebesar 10%. Terdapat perbedaan bermakna antara kelompok
responden yang menjalani nefrostomi perkutan dengan yang tidak
(p=0,0470, α=0,05).
Simpulan: hubungan yang signifikan antara nefrostomi perkutan
dan kelangsungan hidup (p=0,0470, α=0,05).
Kata kunci: kanker serviks, nefrostomi perkutaneus, kesintasan,
gagal ginjal
Objective: explore the association between percutaneous
nephrostomy and survival of patients with advanced cervical
cancer accompanied by renal impairment.
Materials and Methods: Retrospective cohort, with 70 samples
taken with consecutive sampling. The population was all
advanced cervical cancer patients with impaired renal function
(IIIB, IVA, IVB, recurrent) treated in RSUPNCM since January 1,
1998. Sample size was each 19 patients for percutaneous
nephrostomy and conservative groups. Survival was measured
from medical records of advanced cervical cancer patients with
impaired renal function who were treated at RSUPNCM since
January 1, 1998 until December 31, 2003. Percutaneous
nephrostomy was measured from medical records of advanced
cervical cancer patients with impaired renal function treated at
RSUPNCM since 1 January 1998 until December 31, 2003.
Results: Median survival of 44 respondents who underwent
percutaneous nephrostomy was 203 days with probability of
survival at 6 months 56.9% and 12 months by 31.1%. Median
survival of 26 respondents who did not undergo percutaneous
nephrostomy was 75 days with a chance of survival at 6 months
26.6% and 12 months 10%. There were significant differences
between patients undergoing percutaneous nephrostomy and those
without (p = 0.0470, α = 0.05).
Conclusion: There was significant association between
percutaneous nephrostomy and survival (p = 0.0470, α = 0.05).
Keywords: cervical cancer, percutaneous nephrostomy, survival,
kidney failure
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INTRODUCTION
Cervical cancer is an important issue in gynecologic
oncology field, both in developed countries and
developing countries. Cervical cancer is the fourth most
common cancer in women. Number of cases estimated
in 2012 was 528,000 new cases, with 266,000 deaths
from cervical cancer worldwide.1 Eighty-five percent of
cervical cancer cases occur in developing countries such
as Africa, South America, South Asia, and Southeast
Asia. In Indonesia, cervical cancer ranks first in gyneco-
logical cancers.2
In Indonesia in Obstetrics and Gynecology Department
RSUPN Dr. Cipto Mangunkusumo (RSUPNCM) Jakar-
ta, cervical cancer occupied more than half of all
patients with malignant disease of the reproductive
organs. Each year no less than 250 new cases of cervical
cancer were found. Most patients with cervical cancer
came in late stage (62% in stage II B to IV A), made the
treatment became more complicated.3
According to a research in RSUPNCM by Nuranna et
al. 30% of the late stage cervical cancer had renal
failure due to ureteric obstruction.4 According to the
clinical stage of the International Federation of
Gynecology and Obstetrics (FIGO), hydronephrosis and
renal failure is a sign of clinical stage IIIb. Mishra et al.
reported that the average 5-year survival of cervical
cancer patients without urethral obstruction and normal
kidney function was 47%, whereas if there is obstruct-
ion of the ureter the survival was 29%.5
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Kidney failure in cervical cancer is mostly (90%)
caused by high location of the obstruction in the ureter
due to compression of the tumor mass. Cervical cancer
can spread to surrounding structures including a lower
segment of the uterus, vagina, paracervical and para-
metrial spaces. Distal ureter is in parametrial when the
ureter passes through the pelvic wall to the bladder, and
is about two centimeters from the edge of the cervix.
Expansion of cervical cancer to the parametrial can
cause distal ureter being wrapped by the tumor, causing
hidroureteronephrosis and finally a kidney failure.6
There are several ways of handling ureteral obstruction
in late stage cervical cancer with impaired renal func-
tion such as conservative, hemodialysis, percutaneous
nephrostomy, retrograde ureteral stent, antegrade
ureteral stent and bypass nephrovesical. According to
Dagli et al. (2011) and Demetriu et al. (1996), high
obstruction location, ureterovesical junctions involve-
ment, and external compression causing difficulties to
free the obstruction through the installation of cyto-
scopy retrograde ureteral catheter from below.7,8
Percutaneous nephrostomy is a process constructing a
fistula that connects the kidney collecting system to the
skin. This action according to Demetriu et al. (1996)
and Ahmed et al. (1995) can resolve obstruction with a
fairly high success rate.8,9
Until now, Obstetrics and Gynecology Department
RSUPNCM have never studied the effect of percutan-
eous nephrostomy to the survival of late stage cervical
cancer patients with impaired renal function. There are
no data on what factors that influence the increasing of
life expectancy of the patient. The objective of this
study was to determine the relationship between percu-
taneous nephrostomy and late stage cervical cancer with
impaired renal function survival.
MATERIALS AND METHODS
This study used cohort retrospective study design. The
study population was all late stage cervical cancer
patients with impaired renal function (IIIB, IVA, IVB,
recurrent) who were treated in RSUPNCM since
January 1, 1998. Based on calculation, the amount of
samples assigned was 19 people each for percutaneous
nephrostomy and conservative groups. Samples were
taken in sequence (consecutive sampling). There were
two kinds of variable examined, dependent variable
(survival) and independent variables (percutaneous
nephrostomy). Survival was measured by taking the
data from medical records of late stage cervical cancer
patients with impaired renal function who were treated
at RSUPNCM since January 1st, 1998 until December
31st, 2003. Home visits were performed if the patient
did not follow the re-examination after discharge from
hospital. Form of checklist was sent to the patients who
reside outside Jakarta to be filled in and sent back, or
contacted by phone.
Nephrostomy percutaneous measured by taking the data
from the medical records of late stage cervical cancer
patients with impaired renal function treated at
RSUPNCM since January 1st, 1998 until December
31st, 2003. To determine the relationship between
percutaneous nephrostomy with survival, life table and
the Kaplan-Meier tests were used, and to see the
significance log rank test and Wilcoxon at 95% confi-
dence level were used.
RESULTS AND DISCUSSION
Table 1. Table of survival of late stage cervical cancer
with impaired renal function and percutan-
eous nephrostomy versus conservative
Group Number of
Respondents
Survival
Median
Probability
of 6 Month
Survival
Probability
of 12
Month
Survival
Percutaneous
nephrostomy
44 people 203
days
56.9% 31.1%
Conservative 26 people 75 days 26.6% 10%
Survival median of 44 respondents who underwent
percutaneous nephrostomy is 203 days with probability
of survival in 6th month was 56.9% and in the 12th was
31.1%. Survival median of 26 respondents who did not
undergo percutaneous nephrostomy is 75 days with a
chance of survival in 6th month was 26.6% and at
month 12 by 10%.
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Figure 1. Graph of survival according to the
intervention
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Percutaneous nephrostomy, first described by Goodwin
et al. in 1955, is a construction of fistula that connects
the kidney collecting system to the skin. Indications of
percutaneous nephrostomy were for the repair of urinary
obstruction, diagnostic examinations, access to thera-
peutic interventions, and urinary diversion.7
There is no absolute contraindication to percutaneous
nephrostomy. In patients with metabolic disorders and
life-threatening electrolyte, dialysis can be performed
prior to percutaneous nephrostomy. Coagulopathy
should be corrected whenever possible.7
Percutaneous nephrostomy is performed with the
following steps. After asepsis and antisepsis and
infiltration of local anaesthetic agent, small incision is
made. Inferior calix unidirectional puncture is done with
a needle number 18 or 12 in the direction of calix
inferior and with ultrasound guidance. If the position is
right, urine will leave immediately after the stylet is
released from the needle. A guide wire is inserted
through the needle and placed on the kidney collecting
system until pielum or proximal ureter, and then the
needle is pulled out. Number 8 F nephrostomy catheter
can be inserted through a guide wire and placed on
kidney collecting system. The catheter is then fixed to
the skin with sutures wearing non-absorbable threads
and connected with urine closed container.1
Figure 2. Insertion of a percutaneous nephrostomy
catheter. (Image and caption adapted from
Smith & Tanagho's General Urology, Chap-
ter 8).
Notes: A: J guidewire inserted through the
needle-sheath system and driven with the help of
a plastic sheath into the renal pelvis. B: Insertion
of coaxial dilator/introducer sheath system
outside the guidewire. Rigid proximal portion of
the Lunderquist guidewire prevent bending
outside the kidney. C: Once the dilator has
entered the collecting system, introducer sheath
was pushed through the ends. D: Pigtail
nephrostomy catheter is inserted into the renal
pelvis through the guidewire and through the
introducer sheath.13
Based on the logrank test analysis, there were
significant differences between the group of respondents
who underwent percutaneous nephrostomy with the
patients who did not. (p=0.0470, α=0.05). The death risk
value in late stage cervical cancer patients with impaired
renal function (LSCCPIRF) with the conservative type
of intervention or did not undergo the percutaneous
nephrostomy was 1.78 times greater (95% CI 1.00 to
3.16; p=0.050) compared with the patients whom
percutaneous nephrostomy was performed, after the
factors were controlled in the multivariate analysis, the
risk value changed to 2.43 (95% CI 1.10; 5.39)
(p=0.029).
According to Gasparini et al. (1991), the average of
survival median after percutaneous nephrostomy is 526
days, and (range 1-712 days), research on prostate
cancer, the overall survival was 57% at 1 year and 29%
at 2 years (median survival 21 months). Another study
on prostate cancer survival rate was overall 60% at 1
year and 32% at 2 years.
Harrington et al. (1995), stated that median survival in
all patients with ureteral obstruction due to malignancy
was 133 days (range 7-712). Seventeen patients were
still alive (40%) at 6 months and 5 (12%) at 1 year.
According to Romero et al. (2005), the average survival
rate after percutaneous nephrostomy in patients with
cervical cancer were 49.2% at 6 months and 36.9% at
12 months.
CONCLUSION
Based on the research, it is known that there is strong
relationship between percutaneous nephrostomy with
(LSCCPIRF) survival. Patients who underwent nephro-
stomy have better survival than patients who did not
undergo nephrostomy. Further studies with an adequate
amount of samples and variables that have been
prepared were needed.
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